Defence Therapeutics Inc.
Defence Therapeutics Inc.: DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA
DGAP-News: Defence Therapeutics Inc.
/ Key word(s): Miscellaneous
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA Vancouver, BC, Canada, October 6th, 2021 – Defence Therapeutics Inc. (“Defence” or the “Company“), a biotechnology company working on cancer therapeutics and infectious disease vaccines is finalizing all required steps in preparation to a pre-IND meeting to initiate a phase I trial against melanoma using its DC cancer vaccine candidate AccuVAC-D002. Defence has successfully exploited the use of its AccumTM technology platform to develop a large pipeline of products in immune-oncology and infectious diseases. Amongst its lead products is AccuVAC-D002, a DC-based cancer vaccine engineered to treat melanoma. The AccumTM technology platform is very efficient at enhancing intracellular delivery of proteins of pharmacological interests such as ADCs or vaccine antigens. Defence’s scientific team recently identified a novel function for the use of “free” AccumTM and its recently developed variants as anti-cancer molecules. Defence Therapeutics has antibody-drug conjugates and vaccines in late-stage pre-clinical development and/or undergoing GLP studies. With two DC cancer vaccines (AccuVAC-D001 and D002) undergoing manufacturing in clean rooms, Defence is most likely to initiate its Phase I trials in Q1/Q2 of 2022. Skin Cancer Treatment Market to reach USD 14.55 Billion with a 7.5% CAGR by 2027, according to a report by Fortune Business InsightsTM. For further information:
06.10.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Defence Therapeutics Inc. |
1680 – 200 Burrard St | |
V6C3L6 Vancouver | |
Canada | |
E-mail: | info@defencetherapeutics.com |
Internet: | https://defencetherapeutics.com |
ISIN: | CA24463V1013 |
WKN: | A3CN14 |
Listed: | Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto |
EQS News ID: | 1238582 |
End of News | DGAP News Service |